Literature DB >> 1748035

Tolerance and rebound to H2-receptor antagonists: intragastric acidity in patients with duodenal ulcer.

C H Wilder-Smith1, F Halter, H S Merki.   

Abstract

Tolerance to the antisecretory effects of H2-receptor antagonists develops consistently in healthy volunteers. The aim of this study was to determine whether tolerance occurs with repeated dosing of H2-receptor antagonists in patients with duodenal ulcer. Continuous intragastric 24-hr pH measurements were performed in 12 patients with duodenal ulcer in symptomatic remission before, on days 1 and 29, and two days after receiving ranitidine 300 mg four times a day for 34 days. The 24-hr median intragastric pH (interquartile range) was 5.4 (4.4-6.1) on day 1 and 4.6 (4.0-5.2) on day 29 of dosing with ranitidine (not significant). Median nighttime pH was 6.8 (6.3-7.0) on day 1 and 6.8 (6.6-7.1) on day 29 (not significant). During the daytime, the median pH decreased marginally from 4.7 (3.8-5.2) on day 1 to 3.8 (3.0-4.6) on day 29 (P less than 0.03). There was no difference in median intragastric pH during 24-hr, day and night periods before and two days after ranitidine dosing. No significant tolerance or rebound to H2-receptor antagonists was observed in patients with duodenal ulcer disease. This contrasts with data gathered in healthy volunteers and may be due to defects in the regulation of acid secretion in duodenal ulcer disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1748035     DOI: 10.1007/bf01296610

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  32 in total

1.  A comparison of the nocturnal gastric secretion in patients with duodenal ulcer and in normal individuals.

Authors:  E LEVIN; J B KIRSNER
Journal:  Gastroenterology       Date:  1948-06       Impact factor: 22.682

2.  Rebound nocturnal hypersecretion after four weeks treatment with an H2 receptor antagonist.

Authors:  G M Fullarton; G McLauchlan; A Macdonald; G P Crean; K E McColl
Journal:  Gut       Date:  1989-04       Impact factor: 23.059

3.  Tolerance to intravenous ranitidine.

Authors:  P E Hyman; T Q Garvey; C E Abrams
Journal:  J Pediatr       Date:  1987-05       Impact factor: 4.406

4.  The effectiveness of ranitidine in reducing gastric acid-secretion decreases with continued therapy.

Authors:  P J Prichard; D B Jones; N D Yeomans; G W Mihaly; R A Smallwood; W J Louis
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

5.  Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression.

Authors:  D W Burget; S G Chiverton; R H Hunt
Journal:  Gastroenterology       Date:  1990-08       Impact factor: 22.682

6.  Effects of eight weeks' continuous treatment with oral ranitidine and cimetidine on gastric acid secretion, pepsin secretion, and fasting serum gastrin.

Authors:  R Mohammed; R J Holden; J B Hearns; B M McKibben; K D Buchanan; G P Crean
Journal:  Gut       Date:  1983-01       Impact factor: 23.059

7.  Effect of one-month treatment with cimetidine on gastric secretion and serum gastrin and pepsinogen levels.

Authors:  K F Sewing; L Hagie; A F Ippoliti; J I Isenberg; I M Samloff; R A Sturdevant
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

8.  Loss of acid suppression during dosing with H2-receptor antagonists.

Authors:  C Wilder-Smith; F Halter; T Ernst; M Gennoni; B Zeyen; L Varga; J J Roehmel; H S Merki
Journal:  Aliment Pharmacol Ther       Date:  1990       Impact factor: 8.171

Review 9.  Review: antisecretory drugs: cellular mechanisms of action.

Authors:  A H Soll
Journal:  Aliment Pharmacol Ther       Date:  1987-04       Impact factor: 8.171

10.  Sensitivity of the parietal cell to pentagastrin in health and duodenal ulcer disease: a reappraisal.

Authors:  F Halter; U Bangerter; W H Häcki; M Schlup; L Varga; S Wyder; A Rotzer; R Galeazzi
Journal:  Scand J Gastroenterol       Date:  1982-06       Impact factor: 2.423

View more
  3 in total

Review 1.  Optimizing acid suppression for treatment of acid-related diseases.

Authors:  R H Hunt; C Cederberg; J Dent; F Halter; C Howden; I N Marks; S Rune; R P Walt
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

2.  Reversible pheripheral edema in female patients taking proton pump inhibitors for peptic acid diseases.

Authors:  G Brunner; C Athmann; J H Boldt
Journal:  Dig Dis Sci       Date:  2001-05       Impact factor: 3.199

3.  Attenuated Salmonella typhimurium carrying the hepatocyte growth factor and keratinocyte growth factor genes repairs gastrointestinal mucosal damage caused by chemotherapy.

Authors:  Jun-Zhong Sun; Xiao-Qin Ha; Li-Ming Zhang; Hai-Bin Wang; Hong-Wei Wang; Hai-Feng Duan
Journal:  Med Oncol       Date:  2013-01-19       Impact factor: 3.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.